Formulation and clinical translation of [ <sup>177</sup> Lu]Lu-trastuzumab for radioimmunotheranostics of metastatic breast cancer
Mohini Guleria(Bhabha Atomic Research Centre), Tapas Das(Bhabha Atomic Research Centre), Venkatesh Rangarajan(Tata Memorial Hospital), Haladhar Dev Sarma(Bhabha Atomic Research Centre), Jeyachitra Amirdhanayagam(Bhabha Atomic Research Centre), Rohit Sharma(Institute of Medical Sciences), Ashutosh Dash(Bhabha Atomic Research Centre)
Cited by 33
Related Papers
Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis
|European Journal of Nuclear Medicine and Molecular Imaging|2011|377
Production of 177Lu for Targeted Radionuclide Therapy: Available Options
|Nuclear Medicine and Molecular Imaging|2015|375
Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial
|Journal of Clinical Oncology|2021|338
Sustained Availability of <sup>99m</sup>Tc: Possible Paths Forward
|Journal of Nuclear Medicine|2012|140